Dividend Calculator Dividend Returns Comparison Dividend Calendar

My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors

Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Beyondspring Inc (BYSI)

NASDAQ:BYSI

BYSI

Beyondspring

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding BYSI?

Track your performance easily

Link Broker

Beyondspring (BYSI) Stock News & Sentiment

323 Followers

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

Premium

Press Releases

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

10d ago

BYSI

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

Premium

Press Releases

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

10d ago

BYSI

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Premium

Press Releases

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

23d ago

BYSI

BeyondSpring Inc. Reports Mid-Year Financials

Premium

Company Announcements

BeyondSpring Inc. Reports Mid-Year Financials

28d ago

BYSI

SEED and Eisai Partner on Groundbreaking Biotech Research

Premium

Company Announcements

SEED and Eisai Partner on Groundbreaking Biotech Research

2M ago

BYSI

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

Premium

Press Releases

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

2M ago

BYSI

BeyondSpring Inc. Announces Share Issuance

Premium

Company Announcements

BeyondSpring Inc. Announces Share Issuance

4M ago

BYSI

More BYSI News >

BYSI News on the Web

2024-09-16

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

Yahoo Finance

Neutral

2024-09-16

Yahoo Finance

Neutral

2024-09-10

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

Yahoo Finance

Neutral

2024-09-03

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Yahoo Finance

Neutral

2024-08-31

Is BeyondSpring In A Good Position To Invest In Growth?

Yahoo Finance

Neutral

2024-08-29

BeyondSpring Inc. Reports Mid-Year Financials

TipRanks News

Neutral

2024-08-06

SEED Therapeutics Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

Yahoo Finance

Neutral

2024-06-12

BeyondSpring Inc. Announces Share Issuance

TipRanks News

Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score

Media Buzz

This Week0 articles

Weekly Average0 articles

News Sentiment

Currently, no data available

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BYSI’s Media Buzz Sentiment?

Currently, no data Available

What is BYSI’s weekly average amount of articles?

Currently, no data Available

What is BYSI’s News Sentiment?

Currently, no data Available

Healthcare Stocks that are Trending in the News

WVEWave Life Sciences

ZVRAZevra Therapeutics

IDYAIDEAYA Biosciences

VTYXVentyx Biosciences

HRMYHarmony Biosciences Holdings

Showing the stocks with the most bullish news sentiment over the past week

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing